Neuphoria Therapeutics Inc. (NEUP) - 10-K Summary
Business Context and Reporting Period
Reporting Period: Fiscal year ended June 30, 2026.
Company Status: Neuphoria is a clinical-stage biotechnology company that redomiciled from Australia to Delaware in December 2024. Following the failure of its Phase 3 AFFIRM-1 trial for Social Anxiety Disorder (SAD) in October 2025, the company discontinued the SAD program and paused its PTSD program. The company has undergone significant restructuring, terminating facility leases and retaining only one full-time employee, relying on consultants for operations.
Strategic Transaction: On July 23, 2026, Neuphoria entered into a Merger Agreement with Scancell Holdings plc. The transaction is subject to customary closing conditions, including shareholder approvals and Scancell raising at least $75.0 million in gross proceeds. If completed, Neuphoria shareholders will receive Scancell ADSs and Contingent Value Rights (CVRs) tied to future proceeds from partnered programs and tax credits.
Key Financial Metrics
| Metric | Fiscal 2026 | Fiscal 2025 |
|---|---|---|
| Revenue | $1.17 million | $15.65 million |
| Net Loss | $(13.59) million | $(0.84) million |
| Operating Cash Flow | $(12.35) million | $0.08 million |
| Cash and Cash Equivalents (End of Period) | $19.9 million | $14.2 million |
| Accumulated Deficit | $(191.8) million | $(178.2) million (implied) |
| Goodwill Impairment Charge | $5.36 million | $0 |
| Restructuring Costs | $1.28 million | $0 |
Note: Revenue in 2025 included a $15.0 million milestone payment from Merck. Revenue in 2026 was primarily driven by a $1.42 million distribution from the CTx CRC collaboration.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased 92.5% year-over-year, primarily due to the absence of the non-recurring $15.0 million Merck milestone payment received in the prior year.
- Increased Losses: Net loss increased significantly to $13.6 million, driven by a $5.4 million non-cash goodwill impairment charge (triggered by Merck terminating its MK-1167 Alzheimer's trial) and $1.3 million in restructuring costs.
- Expense Reduction: Research and Development (R&D) expenses decreased 60.6% to $3.5 million due to the pause in internal clinical trials and workforce reduction. General and Administrative (G&A) expenses remained relatively flat, decreasing slightly by 4.3%.
- Capital Raising: The company raised approximately $18.5 million through its At-The-Market (ATM) facility during the fiscal year, contributing to a net increase in cash despite operating losses.
Guidance, Outlook, and Risks
Outlook: Management believes existing cash resources ($19.9 million) are sufficient to fund operations beyond the second quarter of fiscal 2028, assuming the current cost-reduced operating plan continues. The primary focus is completing the merger with Scancell.
Management Commentary: The company has ceased active internal R&D. The BNC210 PTSD program remains "clinic-ready" but paused. Scancell has stated it does not intend to develop Neuphoria's non-partnered assets post-merger, focusing instead on maintaining IP and collecting proceeds via CVRs.
Key Risks and Contingencies:
- Merger Uncertainty: The proposed merger is subject to multiple closing conditions, including regulatory approvals, financing by Scancell, and maintaining a minimum net cash balance of $10.0 million. Failure to close could lead to liquidation.
- Internal Control Weakness: The company identified a material weakness in internal controls regarding the evaluation of goodwill for impairment, specifically the failure to timely identify triggering events.
- Going Concern: While management currently asserts no substantial doubt about the ability to continue as a going concern for the next 12 months, this is contingent on the merger or securing additional financing if the merger fails.
- Partner Dependency: Future revenue is heavily dependent on milestones and royalties from partners (Merck, Pfizer/CTx CRC, Carina Biotech), over which Neuphoria has limited control.
Investor Verification Checklist
- Merger Closing Conditions: Verify the status of Scancell's concurrent financing ($75M target) and the effectiveness of the Form F-4 registration statement.
- Cash Runway: Confirm the current cash balance and burn rate to ensure the $10.0 million closing net cash condition for the merger can be met by December 31, 2026.
- Goodwill Impairment: Review the valuation methodology used for the $5.4 million impairment charge and assess the likelihood of further impairments if partner programs (e.g., Merck's MK-4334) face setbacks.
- Internal Controls: Monitor the remediation plan for the material weakness in goodwill impairment controls to ensure future financial reporting accuracy.
- Warrant Liability: Review the terms of the amended warrant agreement with Armistice Capital, specifically the "Cash-Out Right" and potential equity consideration in the merger.